DNTH

Dianthus Therapeutics Inc. (DNTH) | Rumor.io

Dianthus Therapeutics

DNTH

Attention (50-day avg)0%

Attention rank (50-day avg)#1,787

Bullish sentiment (50-day avg)86%

Price to earnings ratio3.3

Market capitalization4.8B

Earnings per share-4.21

Dividend yield (TTM)—

Revenue (annual)2M

Net income (annual)-162.3M

Social

What share of all stock conversation is about DNTH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jun 28

Dianthus Therapeutics, Inc. (DNTH) is considered a potential fit for a specific investment strategy.
The commenter believes the user's action on DNTH is driven by Fear Of Missing Out (FOMO).
The user is uncertain about the direction of DNTH.

Generated by AI

Sentiment

Of the messages about DNTH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	84.62% -15.38	91.04% +12.89
Bearish	—	—	15.38% +15.38	8.96% -12.89

Bullish· Mar 10

Dianthus Therapeutics, Inc. ($DNTH) was upgraded to Strong Buy from Outperform at Raymond James with a new price target of $123.
The company's interim Phase 3 CAPTIVATE update showed a responder rate of over 50% in CIDP patients, potentially accelerating its development timeline and narrowing its time-to-market.
Baird, Raymond James, and Wedbush have all raised their price targets for $DNTH, with Baird setting a new target of $132 and Raymond James setting a new target of $123.

Bearish· Dec 13

The company is likely to experience dilution, as evidenced by the issuance of new shares for shorting.
The stock is oversold and due for a violent reversal, which could result in a significant price drop.
The company's recent news is seen as a way to dilute the stock and attract new investors, rather than a genuine catalyst for growth.

Generated by AI

Topics

Of the messages about DNTH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	93.4%	71.37%
Analysts	—	—	6.6%	5.07%
Technical Analysis	—	—	0%	22.17%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.3%
Macro	—	—	0%	1.09%

Mar 11

Dianthus Therapeutics, Inc. priced an upsized $625 million underwritten public offering at $81 per share.
The company will use the funds raised to develop its pipeline of treatments for autoimmune diseases.
The offering was successful, with Dianthus Therapeutics issuing 7,313,582 shares of common stock.

Generated by AI

Community

Of the messages about DNTH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	95.65%	38.95%
Newcomers	—	100%	4.35%	61.05%

Regulars· Mar 9

Dianthus Therapeutics has accelerated the development of its CIDP drug, Claseprubart, after positive interim trial data, with the company making an early GO decision in the Phase 3 CAPTIVATE trial.
The company's shares surged 26% to $82.36 after the news, and have been advancing with a 28.64% increase today, following the early GO decision and positive trial data.
Dianthus Therapeutics has reported recent business achievements, including the GO decision, and has announced Q4 and FY 2025 financial results, with the company also proposing a $400 million underwritten public offering.

Newcomers· Jun 28

New investors are considering Dianthus Therapeutics, Inc. (DNTH) as part of their investment strategy.
Some newcomers believe that the current market sentiment towards DNTH is driven by Fear Of Missing Out (FOMO).
Newcomers are seeking guidance on DNTH's potential direction and whether it will continue to move in a certain way.

Generated by AI

Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The capital raise comes after a sharp pullback in Dianthus Therapeutics' share price. The stock fell 4.99% over the last session, 8.83% across the past week and 15.11% over 30 days. However, the 90-day share price return of 2.04% and a year-to-date share price gain of 135.48% suggest that momentum has...

7d agofinance.yahoo.com

Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run

Dianthus Therapeutics has delivered a very large 3 year return, which puts a lot of focus on whether the current share price still lines up with what its balance sheet actually supports. With the stock last closing at US$93.44, the open question is how that level stacks up against the book value backing each share. Over the past 3 years the stock has gained roughly 7x. Anyone looking at Dianthus Therapeutics now has to ask whether that kind of move is still grounded in the company’s...

7d agoYahoo Finance

JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating

Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $139.36, accordin

20d agofinance.yahoo.com

Dianthus Therapeutics at Cantor conference: pipeline gains speed

20d agoInvesting.com

Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement

25d agoSeeking Alpha

Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen

On August 4, Dianthus Therapeutics (NASDAQ:DNTH) reported second-quarter 2026 results alongside a stack of pipeline updates that touched nearly every program the company runs. For a clinical-stage biotech with no approved product yet, the update reads less like a routine earnings drop and more like a status report on three separate autoimmune disease bets happening […]

26d agofinance.yahoo.com

Also Discussed

Investors talking about DNTH also mention

#	Name	Attention
1	UroGen Pharma Ltd.URGN	0%new
2	Rhythm Pharmaceuticals, Inc.RYTM	0%new
3	Roivant Sciences Ltd.ROIV	0%+0
4	Fortrea Holdings Inc.FTRE	0%0
5	Vestis CorporationVSTS	0%0
6	Integra LifeSciences Holdings CorporationIART	0%0
7	Bruker CorpBRKR	0%+0
8	Insight Enterprises, Inc.NSIT	0%0
9	Acadia Healthcare Company, Inc.ACHC	0%0
10	CareDx IncCDNA	0%-0.01

Dianthus Therapeutics Inc.

Healthcare
Biotechnology

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for severe autoimmune and inflammatory diseases. The company is centered on complement-targeting science, with a portfolio of monoclonal antibodies and fusion proteins designed to selectively modulate immune pathways involved in disease activity. Its lead programs include claseprubart, an engineered antibody designed to inhibit the active C1s complement protein, and DNTH212, a bifunctional fusion protein that combines immune-cell targeting with suppression of B-cell signaling. Dianthus Therapeutics Inc. is advancing these candidates for conditions such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. The company’s role in the market is to develop differentiated antibody-based treatments aimed at patients with serious immune-mediated disorders that have limited therapeutic options.

Website

Location

7 Times Square

New York, NY, 10036

United States

Social

What share of all stock conversation is about DNTH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jun 28

Dianthus Therapeutics, Inc. (DNTH) is considered a potential fit for a specific investment strategy.
The commenter believes the user's action on DNTH is driven by Fear Of Missing Out (FOMO).
The user is uncertain about the direction of DNTH.

Generated by AI

Sentiment

Of the messages about DNTH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	84.62% -15.38	91.04% +12.89
Bearish	—	—	15.38% +15.38	8.96% -12.89

Bullish· Mar 10

Dianthus Therapeutics, Inc. ($DNTH) was upgraded to Strong Buy from Outperform at Raymond James with a new price target of $123.
The company's interim Phase 3 CAPTIVATE update showed a responder rate of over 50% in CIDP patients, potentially accelerating its development timeline and narrowing its time-to-market.
Baird, Raymond James, and Wedbush have all raised their price targets for $DNTH, with Baird setting a new target of $132 and Raymond James setting a new target of $123.

Bearish· Dec 13

The company is likely to experience dilution, as evidenced by the issuance of new shares for shorting.
The stock is oversold and due for a violent reversal, which could result in a significant price drop.
The company's recent news is seen as a way to dilute the stock and attract new investors, rather than a genuine catalyst for growth.

Generated by AI

Topics

Of the messages about DNTH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	93.4%	71.37%
Analysts	—	—	6.6%	5.07%
Technical Analysis	—	—	0%	22.17%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0.3%
Macro	—	—	0%	1.09%

Mar 11

Dianthus Therapeutics, Inc. priced an upsized $625 million underwritten public offering at $81 per share.
The company will use the funds raised to develop its pipeline of treatments for autoimmune diseases.
The offering was successful, with Dianthus Therapeutics issuing 7,313,582 shares of common stock.

Generated by AI

Community

Of the messages about DNTH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	95.65%	38.95%
Newcomers	—	100%	4.35%	61.05%

Regulars· Mar 9

Dianthus Therapeutics has accelerated the development of its CIDP drug, Claseprubart, after positive interim trial data, with the company making an early GO decision in the Phase 3 CAPTIVATE trial.
The company's shares surged 26% to $82.36 after the news, and have been advancing with a 28.64% increase today, following the early GO decision and positive trial data.
Dianthus Therapeutics has reported recent business achievements, including the GO decision, and has announced Q4 and FY 2025 financial results, with the company also proposing a $400 million underwritten public offering.

Newcomers· Jun 28

New investors are considering Dianthus Therapeutics, Inc. (DNTH) as part of their investment strategy.
Some newcomers believe that the current market sentiment towards DNTH is driven by Fear Of Missing Out (FOMO).
Newcomers are seeking guidance on DNTH's potential direction and whether it will continue to move in a certain way.

Generated by AI

Dianthus Therapeutics

Social

Jun 28

Sentiment

Bullish· Mar 10

Bearish· Dec 13

Topics

Mar 11

Community

Regulars· Mar 9

Newcomers· Jun 28

News

Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?

Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run

JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating

Dianthus Therapeutics at Cantor conference: pipeline gains speed

Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement

Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen

Also Discussed

Dianthus Therapeutics Inc.

Company Information

Location

News

Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?

Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run

JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating

Dianthus Therapeutics at Cantor conference: pipeline gains speed

Dianthus: Hold, Based On Competitor C1s' CIDP Setback And Continued Claseprubart Advancement

Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen

Also Discussed

Social

Jun 28

Sentiment

Bullish· Mar 10

Bearish· Dec 13

Topics

Mar 11

Community

Regulars· Mar 9

Newcomers· Jun 28